202-CoV

202-CoV
Vaccine description
Target	SARS-CoV-2
Vaccine type	Protein subunit
Clinical data
Routes of; administration	Intramuscular

202-CoV is a COVID-19 vaccine candidate developed by Shanghai Zerun Biotechnology Co., Ltd., Walvax Biotech.^[1]^[2]^[3] It is one of several candidates under development by Walvax.

Development

In May 2020, the Bill & Melinda Gates Foundation awarded Shanghai Zerun Biotechnology a $1,000,000 USD vaccine development grant to "support research and development for COVID-19 response".^[4]

In July 2021, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that it had partnered with Shanghai Zerun Biotechnology and its parent company, Walvax Biotech, to develop COVID-19 vaccine candidates against both the original strain of SARS-CoV-2 and its newer variants.^[3] As of October 2022, CEPI had provided up to $25.1 million USD towards 202-CoV, but had ceased further funding.^[5] The chimeric protein candidate remains in Phase I clinical trials.

References

^ Clinical trial number NCT04982068 for "Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
^ Clinical trial number NCT04990544 for "Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell)" at ClinicalTrials.gov
^ ^a ^b "CEPI partners with Shanghai Zerun Biotech to develop COVID-19 variant vaccine". Coalition for Epidemic Preparedness Innovations. 21 July 2021. Retrieved 30 August 2021.
^ "Shanghai Zerun Biotechnology Co., Ltd". Bill & Melinda Gates Foundation. May 2020. Archived from the original on 21 October 2022. Retrieved 21 October 2022.
^ "Our portfolio". Coalition for Epidemic Preparedness Innovations (CEPI). Archived from the original on 21 October 2022. Retrieved 21 October 2022.